BridgeBio Pharma, Inc.· BBIO

🇺🇸 US · LargeBroad USNASDAQ

Healthcare Biotechnology Website

Price: $66.61
Day: -1.04%
Mkt Cap: $13.05B
52W Range: $48.78 – $93.42
Volume: 4.10M
Beta: 0.97

D35D Framework

Valuation Analysis

Intrinsic-value engines paired with peer-anchored multiples.

Valuation: 1.0 / 5 (Well above estimate); at $66.61 the price is 79% above the blended estimate of $14
Estimates: sector peers $14 (87 companies), own 10-year history $122

Blog

Valuation Assessment

BBIO Valuation Summary

How sector peers and the stock's own history value it (no intrinsic model available for this stock)

Overall valuation

1.0/5

Well above estimate

Market only · blended estimate

$14-79.3%

Based on the market evidence from peers and the stock's own history, the price is 79% above the market estimate.Last updated September 21, 2026.

Valuation Multiples

Per-metric breakdown of how BBIO is priced relative to its sector peers, its own 10-year history, and analyst forward estimates.

Valuation context: This company is currently unprofitable with negative EBITDA. P/E and EV/EBITDA aren't meaningful; focus on EV/FCF and FCF Yield in the primary grid, plus revenue multiples (P/S, EV/Sales) in the expanded section.

What sector peers imply

Value if it traded at the sector-median multiple

What its own history implies

Value if it traded at its own 10-year median multiple

How the Multiples lens works

Five primary multiples surface the headline call; five additional multiples sit one click deeper for context.

Valuation multiples compare a company's market price to its financial fundamentals. The primary grid covers both the equity perspective (P/E, PEG, FCF Yield) and the enterprise value perspective (EV/EBITDA, EV/FCF) so you see how the market prices the company two ways simultaneously.

Price-based multiples use market cap and reflect what equity investors pay. EV-based multiples include debt and are better for comparing companies with different capital structures. The expanded section below adds P/B, P/S, P/FCF, EV/EBIT, and EV/Sales for additional perspective.

Learn more about the 5D valuation methodology

BridgeBio Pharma, Inc.· BBIO

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer

Search stocks

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer